1335138-49-2

Upstream product

• 1335139-13-3 C₁₄H₂₂N₂O₂ 
• 42195-97-1 4-(Ethyl)cyclohexylamine 
• 1335139-11-1 1-(trans-4-ethylcyclohexyl)-1H-imidazole-4-carbaldehyde 
• 1335139-06-4 5-[(tert-butoxycarbonyl)amino]-2-(methoxycarbonyl)valeric acid 
• 1335139-07-5 dimethyl 2-(3-((tert-butoxycarbonyl)amino)propyl)malonate 
• 1335139-54-2 methyl 5-[(tert-butoxycarbonyl)amino]-2-{[1-(trans-4-ethylcyclohexyl)-1H-imidazol-4-yl]methyl}valerate 

Relevant academic research and scientific papers

CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents -CH2-CHR5-CH2-NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.